Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × sacituzumab govitecan × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Phase 2 Active not recruiting

80 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05520723 2025-12-04

PRIMED

Phase 2 Completed

50 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Breast

Triple Negative Breast Neoplasms

NCT04230109 2025-10-14

NeoSTAR

Phase 2 Recruiting

260 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Phase 2 Not yet recruiting

150 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07151586 2025-09-03

ALTER

Phase 2 Not yet recruiting

260 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03971409 2025-05-02

InCITe

Phase 2 Recruiting

150 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05770531 2025-04-04

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Phase 2 Recruiting

160 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2 Terminated

30 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT02161679 2021-08-19

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

Clinical Trials

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

PRIMED

ELEVATE TNBC

NeoSTAR

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

ALTER

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

InCITe

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer